DaVita HealthCare Partners Inc. (DVA) Downgraded to Underweight at J P Morgan Chase & Co

J P Morgan Chase & Co cut shares of DaVita HealthCare Partners Inc. (NYSE:DVA) from a neutral rating to an underweight rating in a research note published on Monday morning, MarketBeat.com reports.

Other research analysts also recently issued reports about the stock. TheStreet downgraded shares of DaVita HealthCare Partners from a b rating to a c+ rating in a report on Wednesday, August 2nd. Jefferies Group LLC downgraded shares of DaVita HealthCare Partners from a buy rating to a hold rating and upped their price target for the stock from $64.89 to $70.00 in a report on Monday, June 26th. Royal Bank Of Canada reiterated a hold rating and set a $64.00 price target on shares of DaVita HealthCare Partners in a report on Wednesday, September 6th. Zacks Investment Research upgraded shares of DaVita HealthCare Partners from a sell rating to a hold rating in a report on Thursday, August 3rd. Finally, BidaskClub downgraded shares of DaVita HealthCare Partners from a hold rating to a sell rating in a report on Saturday, July 8th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $66.50.

DaVita HealthCare Partners (NYSE:DVA) opened at 54.40 on Monday. The firm has a 50-day moving average price of $58.34 and a 200-day moving average price of $63.00. DaVita HealthCare Partners has a 12 month low of $53.58 and a 12 month high of $70.16. The company has a market capitalization of $10.40 billion, a price-to-earnings ratio of 8.29 and a beta of 0.90.

DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 1st. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.02. The company had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.82 billion. DaVita HealthCare Partners had a net margin of 8.68% and a return on equity of 14.02%. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.01 earnings per share. On average, equities analysts anticipate that DaVita HealthCare Partners will post $3.59 earnings per share for the current fiscal year.

WARNING: “DaVita HealthCare Partners Inc. (DVA) Downgraded to Underweight at J P Morgan Chase & Co” was posted by Stock Observer and is owned by of Stock Observer. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.thestockobserver.com/2017/10/13/davita-healthcare-partners-inc-dva-downgraded-to-underweight-at-j-p-morgan-chase-co.html.

DaVita HealthCare Partners announced that its Board of Directors has authorized a stock repurchase program on Tuesday, October 10th that allows the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Several institutional investors have recently modified their holdings of DVA. BlackRock Inc. grew its stake in shares of DaVita HealthCare Partners by 2,315.8% in the first quarter. BlackRock Inc. now owns 12,892,477 shares of the company’s stock worth $876,303,000 after purchasing an additional 12,358,806 shares during the last quarter. Park West Asset Management LLC boosted its position in DaVita HealthCare Partners by 88.8% during the first quarter. Park West Asset Management LLC now owns 1,856,516 shares of the company’s stock valued at $126,187,000 after acquiring an additional 873,064 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in DaVita HealthCare Partners during the first quarter valued at $31,376,000. PGGM Investments bought a new stake in DaVita HealthCare Partners during the second quarter valued at $28,598,000. Finally, Highbridge Capital Management LLC boosted its position in DaVita HealthCare Partners by 45,626.9% during the first quarter. Highbridge Capital Management LLC now owns 364,215 shares of the company’s stock valued at $24,756,000 after acquiring an additional 365,015 shares during the last quarter. 83.27% of the stock is currently owned by institutional investors.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply